Metabolomics Manufacturers Technological Advancements, Revenue Diversification, Patent Expansions, Cross-border Expansion, Performance Gap Identification, Organizational Growth Plans, Operational Excellence

Metabolomics Market Companies and their Innovations

The global metabolomics market was evaluated at US$ 2.83 billion in 2023 and is expected to reach around US$ 11.32 billion by 2034, growing at a CAGR of 13.43% from 2024 to 2034.

Top Companies in Metabolomics Market are:

• Thermo Fisher
• Agilent
• Metabolon
• Shimadzu Corporation
• Bruker
• Waters Corporation
• Biotree
• LECO Corporation
• Biocrates Life Sciences AG
• Human Metabolome Technologies
• Metware
• Applied Protein Technology
• Creative Proteomics
• Diagnostic Solutions Laboratory

U.S. Import Data from November 2021 to December 2024: Diagnostic and Laboratory Reagents, Shipping Information, and Quantities

Recent Developments

• In September 2024, Trinity Biotech plc, a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including biosensors, announced that it had acquired Metabolomics Diagnostics, an Irish deep-tech company specializing in collaborations in the development of novel biomarkers. Solutions to complex diseases.
• In May 2024, Metabolon, Inc., a global leader in providing metabolomics solutions enabling a variety of life sciences, diagnostics, drug development, and precision medicine, released significant improvements to its service with a new 4-week project turnaround time.
• In June 2022, Ginkgo Bioworks, a leading horizontal platform for cell programming, announced that it had acquired assets from Bitome, a leading point-of-care metabolite company, to accelerate bioproduct development. Bitome has developed technology that uses machine learning to continuously monitor cell culture media, provide rapid insights into cell function, and optimize bioprocess optimization.
• In August 2024, Metabolon, Inc., a global leader in providing metabolomics solutions enabling a variety of life sciences, diagnostics, drug development, and precision medicine applications, is entering into a partnership with the Scottish Early Rheumatoid Arthritis (SERA) Research Study on the Prevalence of Mild Rheumatoid Arthritis may serve as biomarkers of disease risk, progression, and response to therapy in rheumatoid arthritis.
• In June 2024, 23andMe Holdings Inc., a preventive care and treatment company, and Nightingale Health Plc, a leader in biomarker and risk testing, announced a collaboration to test the efficacy and value of Nightingale Health’s clinically validated and cost-effective blood metabolomics panel with a cohort of 23andMe members.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com